tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NPCE Stock Latest News

Neuropace, Inc. Advances in Treating Lennox-Gastaut Syndrome: A Study Update
Company AnnouncementsNeuropace, Inc. Advances in Treating Lennox-Gastaut Syndrome: A Study Update
3d ago
NPCE
NeuroPace, Inc. Reports Record Revenue and Strong Margins in Q2 2025 Earnings Call
PremiumCompany Announcements
NeuroPace, Inc. Reports Record Revenue and Strong Margins in Q2 2025 Earnings Call
2M ago
NPCE
Neuropace’s Innovative Approach to Treating Lennox-Gastaut Syndrome
PremiumCompany Announcements
Neuropace’s Innovative Approach to Treating Lennox-Gastaut Syndrome
3M ago
NPCE
NeuroPace’s Strategic Advancements and Revenue Growth Underpin Buy Rating Despite Challenges
PremiumRatings
NeuroPace’s Strategic Advancements and Revenue Growth Underpin Buy Rating Despite Challenges
3M ago
NPCE
NeuroPace Reports Record Revenue and Raises Guidance
PremiumCompany Announcements
NeuroPace Reports Record Revenue and Raises Guidance
3M ago
NPCE
NeuroPace reports Q2 EPS (26c), consensus (22c)
PremiumThe FlyNeuroPace reports Q2 EPS (26c), consensus (22c)
3M ago
NPCE
NeuroPace: On track to submit Nautilus data to FDA in 2H
Premium
The Fly
NeuroPace: On track to submit Nautilus data to FDA in 2H
3M ago
NPCE
NeuroPace raises FY25 revenue view to $94M-$98M, consensus $94.78M
Premium
The Fly
NeuroPace raises FY25 revenue view to $94M-$98M, consensus $94.78M
3M ago
NPCE
NPCE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
NPCE Upcoming Earnings Report: What to Expect?
3M ago
NPCE
NeuroPace ‘commends’ CMS for maintaining FY25 epilepsy reimbursement structure
PremiumThe Fly
NeuroPace ‘commends’ CMS for maintaining FY25 epilepsy reimbursement structure
3M ago
NPCE
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
PremiumThe Fly
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
4M ago
NPCE
RAPP
NeuroPace Appoints New CFO Amid Strategic Shift
PremiumCompany Announcements
NeuroPace Appoints New CFO Amid Strategic Shift
4M ago
8K
NPCE
NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed
PremiumThe FlyNeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed
4M ago
NPCE
STAA
Femasys appoints Nicholas as CCO
Premium
The Fly
Femasys appoints Nicholas as CCO
5M ago
FEMY
NPCE
NeuroPace Holds Virtual Annual Stockholders Meeting
Premium
Company Announcements
NeuroPace Holds Virtual Annual Stockholders Meeting
5M ago
8K
NPCE
NeuroPace Secures $75 Million Credit Facility with MidCap
PremiumCompany Announcements
NeuroPace Secures $75 Million Credit Facility with MidCap
5M ago
8K
NPCE
Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal
PremiumRatings
Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal
5M ago
NPCE
NeuroPace initiated with a Buy at H.C. Wainwright
PremiumThe Fly
NeuroPace initiated with a Buy at H.C. Wainwright
5M ago
NPCE
NeuroPace: Buy Rating Affirmed Amid Promising NAUTILUS Study Outcomes and Favorable FDA Engagement
PremiumRatings
NeuroPace: Buy Rating Affirmed Amid Promising NAUTILUS Study Outcomes and Favorable FDA Engagement
5M ago
NPCE
Optimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential
PremiumRatingsOptimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential
5M ago
NPCE
NeuroPace’s Promising Prospects: Buy Rating Affirmed Despite Initial Study Setback
Premium
Ratings
NeuroPace’s Promising Prospects: Buy Rating Affirmed Despite Initial Study Setback
5M ago
NPCE
Leerink says NeuroPace results disappointing, sees hope on totality of data
Premium
The Fly
Leerink says NeuroPace results disappointing, sees hope on totality of data
5M ago
NPCE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >